Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Share-based Compensation (2021 - 2025)

Biofrontera has reported Share-based Compensation over the past 5 years, most recently at $289000.0 for Q4 2025.

  • Quarterly results put Share-based Compensation at $289000.0 for Q4 2025, down 3.34% from a year ago — trailing twelve months through Dec 2025 was $728000.0 (down 11.97% YoY), and the annual figure for FY2025 was $951000.0, down 6.67%.
  • Share-based Compensation for Q4 2025 was $289000.0 at Biofrontera, up from $100000.0 in the prior quarter.
  • Over the last five years, Share-based Compensation for BFRIW hit a ceiling of $517000.0 in Q1 2022 and a floor of $100000.0 in Q3 2022.
  • Median Share-based Compensation over the past 5 years was $228000.0 (2023), compared with a mean of $227235.3.
  • Biggest five-year swings in Share-based Compensation: soared 196.9% in 2022 and later crashed 75.0% in 2023.
  • Biofrontera's Share-based Compensation stood at $129000.0 in 2021, then soared by 196.9% to $383000.0 in 2022, then tumbled by 40.47% to $228000.0 in 2023, then skyrocketed by 31.14% to $299000.0 in 2024, then fell by 3.34% to $289000.0 in 2025.
  • The last three reported values for Share-based Compensation were $289000.0 (Q4 2025), $100000.0 (Q3 2025), and $100000.0 (Q2 2025) per Business Quant data.